SCHEMBL244384

SCHEMBL244384

Brc1ccnc2ccccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 2/20 0.56
LOXL2 Q9Y4K0 1/20 0.52
HTR1A P08908 2/20 0.48
ADRA1D P25100 2/20 0.48
ADRA1A P35348 2/20 0.48
ADRA1B P35368 2/20 0.48
MAPT P10636 4/20 0.48
KDM4E B2RXH2 2/20 0.48
EGFR P00533 1/20 0.46
ALDH1A1 P00352 2/20 0.44
MAPK1 P28482 2/20 0.44
CYP3A4 P08684 1/20 0.43
CYP1A2 P05177 2/20 0.43
NPC1 O15118 1/20 0.43
TP53 P04637 1/20 0.43
RAB9A P51151 1/20 0.43
PTK2B Q14289 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
FERMT2 Q96AC1 1/20 0.43
CYP2C9 P11712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29923695 1.00 NCF1 (0.56) NCF1LOXL2HTR1AADRA1DADRA1A
SCHEMBL30976614 0.98 NCF1 (0.54) NCF1LOXL2HTR1AADRA1DADRA1A
Formaldehyde SCHEMBL28759854 0.94 NCF1 (0.50) NCF1LOXL2HTR1AADRA1DADRA1A
Bicarbonate SCHEMBL28387090 0.88 CYP1A2 (0.46) NCF1LOXL2HTR1AADRA1DADRA1A
SCHEMBL29662059 0.84 MAPT (0.58) NCF1MAPTKDM4EEGFRALDH1A1
SCHEMBL14127412 0.84 MAPT (0.58) NCF1MAPTKDM4EEGFRALDH1A1
SCHEMBL428159 0.84 MAPT (0.58) NCF1MAPTKDM4EEGFRALDH1A1
SCHEMBL14919695 0.77 MAPT (0.52) NCF1LOXL2MAPTKDM4EALDH1A1
SCHEMBL1227713 0.75 CYP1A2 (0.60) NCF1LOXL2HTR1AADRA1DADRA1A
SCHEMBL29699887 0.75 CYP1A2 (0.60) NCF1LOXL2HTR1AADRA1DADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 699 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119039347-A Diamino diphosphine tetradentate ligand, preparation method thereof and application thereof in Suzuki cross-coupling reaction 郑州大学 2024-11-29 CN claimed
CN-118439995-A Preparation method of pitavastatin intermediate 3- [ 2-cyclopropyl-4- (4-fluorophenyl) -3-quinolyl ] -2-acrolein 浙江工业大学 2024-08-06 CN claimed
CN-117945995-A Alkylated nitrogen-containing heterocyclic compound and preparation method and application thereof 中国科学院青海盐湖研究所 2024-04-30 CN claimed
CN-117946000-A Synthesis method of 1-methyl-2-oxo-1, 2-dihydro-4-quinolinecarboxylic acid methyl ester 南通大学 2024-04-30 CN claimed
CN-116178258-B N-methylaniline quinoline compound and synthetic method and application thereof 中国医学科学院北京协和医院 2023-11-21 CN claimed
CN-116178258-A N-methylaniline quinoline compound and synthetic method and application thereof 中国医学科学院北京协和医院 2023-05-30 CN claimed
CN-110229102-B 2-alkylated quinoline, derivative and synthetic method thereof 湘潭大学 2022-05-17 CN claimed
CN-112939857-A Synthetic method of alkylated quinoline compound 中国科学院大连化学物理研究所 2021-06-11 CN claimed
CN-109776406-B Method for cross coupling of ether compound and quinoline derivative 湘潭大学 2021-05-04 CN claimed
CN-110229102-A 2- is alkylated quinoline, derivative and its synthetic method 湘潭大学 2019-09-13 CN claimed
CN-105753838-A Novel high-regioselectivity amination method of quinoline derivatives 安阳师范学院 2016-07-13 CN claimed
CN-102898264-B Catalytic preparation process for aromatic nitrile or heteroaromatic nitrile UNIV ZHEJIANG 2014-07-02 CN claimed
EP-0365863-B1 Novel quinolyloxazole-2-ones useful as proteinkinase C inhibitors MERRELL DOW PHARMA (US) 1994-08-17 EP claimed
CN-117024411-B Isoquinoline as HPK1 inhibitor 豪夫迈·罗氏有限公司 2026-05-19 CN disclosed
US-20250360145-A1 CSF-1R INHIBITORS AND USES THEREOF MYROBALAN THERAPEUTICS INC (US) 2025-11-27 US disclosed
US-20250304558-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2025-10-02 US disclosed
US-3974281-A ANALGESICS, ANTI-PYRETIC AND ANTI-INFLAMMATORY AGENTS AFFILIATED MEDICAL RESEARCH, INC. (US) 1976-08-10 US disclosed
US-3953453-A ANTIMALARIAL AGENTS HOFFMANN-LA ROCHE INC. (US) 1976-04-27 US disclosed
US-3931192-A Process for piperidine intermediates for quinine, quinidine and analogs thereof HOFFMANN-LA ROCHE INC. (US) 1976-01-06 US disclosed
US-3931193-A ANTIMALARIA, ANTIARRHYTHMIA INTERMEDIATES HOFFMANN-LA ROCHE INC. (US) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250360145-A1 CSF-1R INHIBITORS AND USES THEREOF CSF1R, CSF3R, IL1RN NCF1 83/4885LOXL2 1962/4885HTR1A 3696/4885
US-20250304558-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY SLC6A11, SCN1A, KCNH1 NCF1 1999/4885LOXL2 3194/4885HTR1A 3303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.